News | August 03, 2008

Abnormal Heart Rate Turbulence Predicts Sudden Death in Patients with CHF

August 4, 2008 – New research shows abnormal heart rate turbulence (HRT), an ECG-based risk marker, is a significant risk predictor for sudden death in patients with congestive heart failure (CHF).

The study published in the August edition of the HeartRhythm Journal, the official journal of the Heart Rhythm Society, is the first to document abnormal HRT as an indicator of sudden, or arrhythmic death risk in patients with heart failure.

The MUSIC (Muerte Subita en Insufficiencia Cardiaca) Study, a multi-center, Spanish, longitudinal study designed to assess risk markers for sudden death in CHF patients, represents the largest heart failure population ever studied. More than 1,000 patients were enrolled in the MUSIC Study between 2003 and 2004 and several risk markers, including Holter-based, were assessed to predict mortality during nearly four years of follow up. Led by principal investigator Antoni Bayes de Luna, M.D., this is the first study to document that HRT predicts not only all-cause mortality and heart failure progression, but also sudden death in patients with heart failure.

“Our study documented that HRT might be considered a useful tool to identify heart failure patients at high risk of death, including high risk of dying suddenly,” said lead author Iwona Cygankiewicz, M.D., Ph.D., cardiology division, University of Rochester Medical Center in New York. “HRT may help physicians more effectively manage heart failure patients by indicating the need for more frequent follow up visits at specialized heart failure units and more intensely applied therapy, including ICD implantation in high risk patients.”

About 50 percent of congestive heart failure-related deaths are due to progressive heart failure, while the other half are thought to be related to serious arrhythmias. Even though HRT was proven as an important risk startifier in postinfarction patients, little is known about its value in patients with heart failure. Previous, smaller studies have proven abnormal HRT as a risk stratifier for all-cause mortality and heart failure progression, but not sudden death.

Patients of the MUSIC study represent a modern population of heart failure patients with a broad spectrum of etiologies. The study population includes patients with heart failure as seen at the ambulatory practice, including a high number of patients with preserved left ventricular ejection fraction (LVEF). Interest is growing in the survival of patients with preserved LVEF and the MUSIC study marks the first time this subgroup was included in a study evaluating the prognostic value of HRT.

For more information: www.heartrhythmjournal.com

Related Content

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Cardiovascular Clinical Studies | August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init